CareDx

The company said 100 US transplant centers provided its AlloSure kidney transplant test to almost 3,400 patients in Q4.

The index's 13 percent gain was below the 39 percent surge of 2017 but occurred despite the poor performance of index stocks in December.

The firm intends to use the proceeds for working capital, general corporate purposes and the potential repayment of indebtedness.

The firm announced in October that had entered into an agreement with Jefferies to sell up to $50 million in shares from time to time.

The company said testing services revenues more than doubled during the quarter as its AlloSure kidney transplant diagnostic continued to penetrate the market.

The company said it intends to use the proceeds for working capital and corporate purposes, including capital expenditures, R&D, clinical trials, and more.

The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.

CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.